每经AI快讯，众生药业1月16日晚间发布公告称，公司第九届第二次董事会会议于2026年1月16日在公 司会议室以现场和通讯表决方式召开。会议审议了《关于控股子公司签署RAY1225注射液项目许可协 议的议案》等文件。 每经头条（nbdtoutiao）——白银50天涨逾80%，疯狂程度远超黄金，历史上爆炒白银往往预示贵金属 牛市已到高潮，这次有何不同？ （记者 王晓波） ...

格隆汇1月16日丨众生药业(002317.SZ)公布，控股子公司广东众生睿创生物科技有限公司（简称"众生 睿创"）与齐鲁制药有限公司（简称"齐鲁制药"）于2026年1月16日签署《许可协议》，众生睿创授权齐 鲁制药在中国地区（包括中国大陆、香港、澳门、台湾，统称"许可地区"）内对RAY1225注射液（简 称"许可产品"）进行生产与商业化销售，众生睿创保留许可知识产权的全部权利、权属和权益，在许可 产品获得药品监管部门上市注册批准后，众生睿创为药品上市许可持有人（MAH）。同时，众生睿创 仍然拥有RAY1225注射液国外的全部权利、权属和权益，包括但不限于临床开发、生产及新药注册、 销售和市场推广。 在满足许可协议约定的条款下，众生睿创将获得首付款及里程碑付款总金额为人民币100,000万元，包 括首付款人民币20,000万元、开发和销售里程碑付款最高合计人民币80,000万元，后续产品上市后有权 获得许可产品净销售额双位数的销售提成。 许可产品RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1 受体和GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一 ...

众生药业公告称，2026年1月16日，其控股子公司众生睿创与齐鲁制药签署《许可协议》，授权齐鲁制 药在许可地区对RAY1225注射液进行生产与商业化销售。众生睿创保留相关知识产权，在产品获批后 为药品上市许可持有人，仍拥有国外全部权益。众生睿创将获首付款及里程碑付款共10亿元，包括2亿 元首付款、最高8亿元开发和销售里程碑付款，后续还有双位数销售提成。本次交易已通过董事会审 议，不构成关联交易和重大资产重组。 ...

众生药业公告，控股子公司众生睿创与齐鲁制药签署许可协议，授权其在中国地区对RAY1225注射液 进行生产与商业化销售。众生睿创将获得首付款及里程碑付款总金额为人民币10亿元，包括首付款人民 币2亿元、开发和销售里程碑付款最高合计人民币8亿元。产品上市后，众生睿创有权获得许可产品净销 售额双位数的销售提成。本次交易已获董事会审议通过，无需提交股东会审议，不构成关联交易或重大 资产重组。 ...

证券代码：002317 公告编号：2026-002 广东众生药业股份有限公司 关于控股子公司签署 RAY1225 注射液项目许可协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1、临床试验研究具有创新强、周期长、投入高、风险大的特点，存在研发 项目推进及研发效果不达预期的风险。 2、协议中所约定的里程碑款及销售提成需要满足一定的条件，最终金额尚 存在不确定性。 一、交易概况 广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众生睿创 生物科技有限公司（以下简称"众生睿创"）与齐鲁制药有限公司（以下简称"齐 鲁制药"）于 2026 年 1 月 16 日签署《许可协议》，众生睿创授权齐鲁制药在中国 地区（包括中国大陆、香港、澳门、台湾，统称"许可地区"）内对 RAY1225 注射液（以下简称"许可产品"）进行生产与商业化销售，众生睿创保留许可知 识产权的全部权利、权属和权益，在许可产品获得药品监管部门上市注册批准后， 众生睿创为药品上市许可持有人（MAH）。同时，众生睿创仍然拥有 RAY1225 注射液国外的全部权利、权属和权益，包括 ...

广东众生药业股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第九届董事会第二次会议 的会议通知于 2026 年 1 月 12 日以专人和电子邮件通知方式送达全体董事，会议 于 2026 年 1 月 16 日在公司会议室以现场和通讯表决方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人。会议由公司董事长陈永红先生主持，董事会秘书 列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。 经与会董事认真审议，以记名投票方式表决，做出如下决议： 证券代码：002317 公告编号：2026-001 一、审议通过了《关于控股子公司签署 RAY1225 注射液项目许可协议的议 案》。 为推动公司创新药上市商业化进程，聚焦创新药研发核心业务，公司同意控 股子公司广东众生睿创生物科技有限公司（以下简称"众生睿创"）与齐鲁制药 有限公司（以下简称"齐鲁制药"）签订《许可协议》，众生睿创授权齐鲁制药 在中国地区（包括中国大陆、香港、澳门、台湾）内对 RAY1225 注 ...

南财智讯1月6日电，众生药业在投资者关系活动中表示，RAY1225注射液治疗中国肥胖/超重患者的III 期临床试验（REBUILDING-2研究）已完成全部参与者入组，单药治疗2型糖尿病患者的III期临床试验 （SHINING-2）入组进展顺利，与司美格鲁肽对照的III期临床试验（SHINING-3）也已完成入组。该药 物具有GLP-1受体和GIP受体双重激动活性，具备每两周注射一次的超长效潜力。2025年12月， RAY1225注射液新增适应症治疗代谢相关脂肪性肝炎（MASH）已获国家药监局批准开展临床试验，临 床前研究显示其可改善NAS评分、降低体重及肝脏脂肪水平，呈现剂量相关性效应。 ...

Group 1: Innovative Drug Development - The company focuses on independent research and development, integrating internal and external resources to address unmet clinical needs, particularly in metabolic and respiratory diseases [1] - As of now, two innovative drug projects have been approved for market launch, with several others in clinical trial stages [1] - The innovative drug ZSP1601, targeting metabolic dysfunction-related fatty liver disease (MASH), has completed Phase Ib/IIa clinical trials, showing significant reductions in liver inflammation markers [3] Group 2: Clinical Trials and Research Progress - RAY1225 injection, a dual agonist for GLP-1 and GIP receptors, is currently undergoing multiple Phase III clinical trials for obesity and type 2 diabetes, with positive results reported in Phase II trials [6][7] - The company is advancing RAY1225 for the treatment of MASH, with preclinical studies indicating improvements in liver inflammation and fibrosis in animal models [9] - The innovative drug Anlavi (昂拉地韦) has been approved for use in treating influenza and is undergoing Phase III trials for children and adolescents [4][6] Group 3: Strategic Investments and Corporate Governance - The company has increased its shareholding in its subsidiary, Zhongseng Ruichuang, to enhance operational control and efficiency in drug development [10] - The focus on innovation is seen as a core driver for the pharmaceutical industry, with the company committed to building a complete industrial layout from research to commercialization [12]

Market Overview - The Shanghai Composite Index rose by 1.38% on January 5, with 26 out of the 28 sectors experiencing gains, led by the media and pharmaceutical industries, which increased by 4.12% and 3.85% respectively [2] - The oil and petrochemical sector and the banking sector were the only ones to decline, with decreases of 1.29% and 0.34% respectively [2] Capital Flow Analysis - The net inflow of capital in the two markets was 8.334 billion yuan, with 15 sectors seeing net inflows [2] - The electronics sector had the highest net inflow, amounting to 9.481 billion yuan, with a daily increase of 3.69% [2] - The pharmaceutical sector also saw significant inflows, with a net inflow of 4.379 billion yuan and a daily increase of 3.85% [2] Pharmaceutical Industry Performance - The pharmaceutical sector rose by 3.85%, with a total of 450 out of 478 stocks in the sector increasing in value, including 22 stocks hitting the daily limit [3] - The top three stocks with the highest net inflow in the pharmaceutical sector were Lepu Medical, with a net inflow of 485 million yuan, followed by Zhongsheng Pharmaceutical and Innovation Medical, with inflows of 293 million yuan and 256 million yuan respectively [3] - The stocks with the highest net outflows included Changshan Pharmaceutical, with a net outflow of 103 million yuan, followed by Hefei China and Tonghua Golden Horse, with outflows of 77.36 million yuan and 75.85 million yuan respectively [5] Top Gainers in Pharmaceutical Sector - Notable gainers included Lepu Medical, which increased by 19.99% with a turnover rate of 9.07% and a capital flow of 484.8 million yuan [4] - Other significant gainers were Zhongsheng Pharmaceutical (up 10.01%, 29.26 million yuan) and Innovation Medical (up 10.00%, 25.64 million yuan) [4] Top Losers in Pharmaceutical Sector - The stocks with the largest losses included Changshan Pharmaceutical (down 1.00%, -102.55 million yuan), Hefei China (down 5.20%, -77.36 million yuan), and Tonghua Golden Horse (down 3.24%, -75.85 million yuan) [5]

Group 1 - The Chinese medicine sector increased by 1.67% on January 5, with Weikang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable individual stock performances include Weikang Pharmaceutical with a closing price of 28.46, up 11.56%, and Zhongsheng Pharmaceutical at 20.88, up 10.01% [1] Group 2 - The net inflow of main funds in the Chinese medicine sector was 511 million yuan, while retail funds saw a net outflow of 219 million yuan [2] - The top stock by main fund inflow was Zhongsheng Pharmaceutical with 253 million yuan, representing 15.19% of its total [3] - The overall trading volume for Zhongsheng Pharmaceutical was 827,200 shares, with a total transaction value of 1.665 billion yuan [1][3]